Clinical Trial Update: JAK-inhibition in Recurrent Classical Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating JAK inhibition in recurrent classical Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Snippet

Sponsor: University of Cologne | Conditions: Recurrent Classical Hodgkin Lymphoma | Phase 2 | Status: COMPLETED